PainReform (PRFX) announced that its pharmaceutical division has completed an R&D assessment of LayerBio’s proprietary drop-less, sustained-release ocular drug-delivery platform. The assessment confirmed that its sustained release, polymer matrix platform can incorporate a variety of drug entities, reinforcing its long-term potential to provide greatly improved pharmacological efficiency and simplify postoperative care for cataract patients by reducing or eliminating the need for medicated eye drops – the DROP-LESS advantage.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRFX:
- PainReform Initiates Phase II Development for OcuRing™-K
- PainReform commences development plan for OcuRing-K Phase II trial
- PainReform Ltd. Announces December 2025 Shareholders Meeting with Key Proposals
- PainReform’s DeepSolar Advances AI Reporting Engine for Solar Assets
- PainReform’s DeepSolar advances development of AI-driven reporting engine